0
No hay productos en el carro de la compra
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Casa > LIGHT

LIGHT

Brief Information

Name:Tumor necrosis factor superfamily member 14
Target Synonym:CD258 Antigen,Herpes Virus Entry Mediator Ligand,TNFSF14,Herpesvirus Entry Mediator Ligand,LIGHT,Tumor Necrosis Factor (Ligand) Superfamily, Member 14,CD258,HVEM-L,Tumor Necrosis Factor Ligand 1D,LTg,HVEML,TNF Superfamily Member 14,Tumor Necrosis Factor Ligand Superfamily Member 14,Tumor Necrosis Factor Superfamily Member 14
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

SCCHO-ATP109-Cell-based assay
 LIGHT FACS

Expression analysis of human LIGHT on CHO/Human LIGHT Stable Cell Line by FACS.
CHO/Human LIGHT Stable Cell Line or negative control cell were stained with PE-labeled anti-Human LIGHT

LIT-H5269-Cell-based assay
 LIGHT CELL

Human LIGHT Protein, Fc Tag (Cat. No. LIT-H5269) induced cytotoxicity in HT-29 cells. The ED50 for this effect is 1.29-2.38 ng/mL (Routinely tested).

LIT-H5256-BLI
 LIGHT BLI

Loaded Human DcR3, Fc Tag (Cat. No. TNB-H5255) on AHC Biosensor, can bind Human LIGHT Protein, Mouse IgG2a Fc Tag (Cat. No. LIT-H5256) with an affinity constant of 1.64 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

LIT-C5244-ELISA
 LIGHT ELISA

Immobilized Human DcR3, Fc Tag (Cat. No. TNB-H5255) at 5 μg/mL (100 μL/well) can bind Cynomolgus LIGHT Protein, His Tag (Cat. No. LIT-C5244) with a linear range of 2-39 ng/mL (QC tested).

Customer Reviews

Synonym Name

CD258 antigen,CD258,HVEM-L,LIGHT,LTg,TNFSF14,TR2,HVEML

Background

Tumor necrosis factor ligand superfamily member 14(LIGHT) is a tumor necrosis factor (TNF) superfamily ligand that regulates T cell immune responses by signaling through the herpes virus entry mediator (HVEM) and the lymphotoxin beta receptor (LTbetaR). LIGHT has emerged as a potent initiator of T cell co-stimulation signals effecting CTL-mediated tumor rejection, allograft rejection and graft versus host disease. Constitutive expression of LIGHT leads to tissue destruction and autoimmune-like disease syndromes.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Quisovalimab CERC-002; AEVI-002; MDGN-002; SAR-252067; AVTX-002 Phase 2 Clinical La Jolla Pharmaceutical Company, Kyowa Hakko Kirin Co Ltd Coronavirus Disease 2019 (COVID-19); Respiratory Distress Syndrome, Adult; Asthma; Colitis, Ulcerative; Acute Lung Injury; Crohn Disease Details
Quisovalimab CERC-002; AEVI-002; MDGN-002; SAR-252067; AVTX-002 Phase 2 Clinical La Jolla Pharmaceutical Company, Kyowa Hakko Kirin Co Ltd Coronavirus Disease 2019 (COVID-19); Respiratory Distress Syndrome, Adult; Asthma; Colitis, Ulcerative; Acute Lung Injury; Crohn Disease Details

This web search service is supported by Google Inc.

totop
Email
Correo electrónico
Fax
Fax
+1 888-377-6111
Address
Address
Lichtstrasse 35,4056 Basel, Switzerland

Dejar un mensaje